NTRS vs PCRX · P/E 18, rev $2.69B vs P/E 174, rev $369.8M
Northern Trust Corporation (NTRS) versus Pacira BioSciences, Inc. (PCRX) — a side-by-side from cached financials, not a winner call.
Northern Trust Corporation (NTRS) is a asset management company listed on US.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported NTRS revenue for 2026-06-30 was $2.69B. Net income was $1.32B. NTRS currently screens at market cap $32.02B and trailing P/E 18.1.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
NTRS currently screens at market cap $32.02B and trailing P/E 18.1. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the NTRS and PCRX stock pages for the full models.
Not investment advice.